CH BIOTECH SER announced its interim results, with a loss attributable to shareholders of HKD 32.06 million, a year-on-year narrowing of 59.95%
I'm PortAI, I can summarize articles.
CH BIOTECH SER announced its mid-term results for 2025, with revenue of HKD 38.872 million, a year-on-year increase of 19.79%; the loss attributable to shareholders was HKD 32.006 million, a year-on-year narrowing of 59.95%; the loss per share was HKD 0.033. The improvement in loss was mainly due to the successful implementation of cost control measures, an increase in gross profit margin, a reduction in administrative expenses, and the receipt of approximately HKD 13.7 million in insurance compensation income
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments